PFIZER INC
Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, markets, sells and distributes medicines and vaccines for people worldwide. It works with healthcare providers, governments and local communities to support access to healthcare. Its products address areas including oncology, internal medicine, vaccines, inflammation and immunology, rare diseases and infectious diseases. Most of its money comes from manufacturing and selling biopharmaceutical products; it also earns money through collaboration and co-promotion arrangements, including with BioNTech for Comirnaty and BMS for Eliquis. Pfizer manages its commercial operations through Biopharma, PC1 and Pfizer Ignite. Biopharma develops and commercializes its products and is its only reportable segment. PC1 provides contract development and manufacturing services and supplies specialty active pharmaceutical ingredients. Pfizer Ignite provides strategic guidance and end-to-end R&D services to select biotech companies and is being wound down. Pfizer supplies medicines and vaccines to approximately 200 countries and territories. It is headquartered in New York, NY.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $PFE in the last 30 days.
See all $PFE insider activity →Pfizer (PFE) filed its quarterly report (10-Q) with the SEC on November 3, 2026. The filing includes financial statements and exhibits, providing an update on the company's performance for the period.
PFIZER INC (PFE) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Pfizer Appoints Cecile Guegan as Chief Financial Officer Cecile Guegan to lead Pfizer’s financial strategy as Chief Financial Officer with over 25 years of pharmaceutical finance experience NEW YORK, November 3, 2026 —Pfizer Inc. (NYSE: PFE) today announced that its
Pfizer, partnering with Sciwind Biosciences, has launched Ecnoglutide, an obesity drug, in China. Pfizer CEO Albert Bourla compared the strategy to Viagra's success, noting the potential for out-of-pocket consumer purchases. The drug was acquired for $495 million, with Pfizer aiming to leverage its experience in self-pay markets. Pfizer also plans global expansion, focusing on berobenatide and other pipeline assets.
Over the past 7 days, AlphAI's AI scored 92 news stories mentioning PFE (PFIZER INC). Coverage has skewed bullish: 61 bullish, 27 neutral, and 4 bearish.
Recent PFE coverage spans market movers, earnings and financial news.
The filing introduces new financial data that could affect valuation.
The CFO change is a material executive transition for a large‑cap pharma company.
The China launch could boost Pfizer's growth outlook as it taps a high‑growth obesity segment, but reimbursement uncertainty adds risk.
Market is discounting the beat-and-raise, with focus shifting to fading COVID revenue and how much upside remains.
Near-term focus is whether the Nov. 3 Q3 report shows cash flow can sustain the dividend despite thin free-cash-flow coverage and expected earnings decline.
AlphAI scores every news story that mentions PFE with an AI model for sentiment and relevance, and aggregates insider trades from PFIZER INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Pfizer (PFE) filed its quarterly report (10-Q) with the SEC on November 3, 2026. The filing includes financial statements and exhibits, providing an update on the company's performance for the period.
1 min readPFIZER INC (PFE) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Pfizer Appoints Cecile Guegan as Chief Financial Officer Cecile Guegan to lead Pfizer’s financial strategy as Chief Financial Officer with over 25 years of pharmaceutical finance experience NEW YORK, November 3, 2026 —Pfizer Inc. (NYSE: PFE) today announced that its
2 min readPfizer, partnering with Sciwind Biosciences, has launched Ecnoglutide, an obesity drug, in China. Pfizer CEO Albert Bourla compared the strategy to Viagra's success, noting the potential for out-of-pocket consumer purchases. The drug was acquired for $495 million, with Pfizer aiming to leverage its experience in self-pay markets. Pfizer also plans global expansion, focusing on berobenatide and other pipeline assets.
2 min readModerna (MRNA) rose 5% ahead of earnings, Pfizer (PFE) fell 0.8% despite raising its 2026 outlook, and Merck (MRK) dropped 2% after launching a new Phase 3 trial. Moderna's stock is up 685% YTD, while Pfizer and Merck are up 29% and 40% YTD, respectively. Each company's stock movement diverged from recent headlines.
7 min readPfizer (PFE) reports Q3 results on Nov. 3, with investors focused on its 5.6% dividend yield. Analysts expect EPS to decline from $2.96 in 2026 to $2.46 by 2028. The dividend used 108% of free cash flow in 2025 and 89% in the 12 months to June 2026, raising concerns about cash coverage.
6 min readPfizer PFE reported Q3 revenue of $16.6B, beating estimates, and raised full-year guidance. Trump announced ending U.S. military aid to Israel by year-end. Spain opened new sanction proceedings against Apple AAPL and Amazon AMZN for alleged anti-competitive practices.
6 min readCoinbase surged 8% after mixed Q3 results and a price target cut. Shopify fell 5% despite revenue near estimates. Bloom Energy rose 10% after an upgrade. Thomson Reuters dropped 7.5% on earnings miss. ON Semiconductor gained 4% on earnings beat. DuPont climbed 9% with raised outlook. Fiserv jumped 12% on strong earnings. AI-related stocks rebounded. Revvity gained 11% on raised guidance. Pfizer eased 1% with earnings beat. Zebra fell 6% despite beating estimates.
7 min readOn Election Day, U.S. stock benchmarks diverged, with the S&P 500, Nasdaq, and Russell 2000 rising, while the Dow fell. Palantir reported $2.313B in Q3 revenue, raising its full-year guidance. NVIDIA announced a $3B investment in Meta. Pfizer's Q3 revenue was $16.6B, with adjusted EPS of $0.87. Apollo reported adjusted net income of $1.3B. Ibotta's Q3 revenue grew 17% to $97.8M.
7 min readPfizer raised its 2026 financial guidance, citing strong growth in oncology and migraine businesses that offset declines in Covid product sales. The company expects these segments to drive future performance.
1 min readPfizer named Cecile Guegan as its new CFO, replacing Dave Denton. Guegan, a 25-year veteran, has served as interim CFO since August. CEO Albert Bourla praised her experience and strategic vision. Pfizer faces industry challenges, including vaccine skepticism.
3 min read
